LETTER TO THE EDITOR

Sprue-Like Enteropathy Associated with Olmesartan: An Unrecognized Emerging Drug-Induced Enteropathy?

Enteropatia Sprue-Like Associada com o Olmesartan: Uma Enteropatia Induzida por Fármaco Emergente e Sub-Diagnosticada?

Dear Editors,

We read with great interest the case reports by da Silva et al.,1 Carneiro et al.2 and Eusébio et al.3 published in the late issue of GE Portuguese Journal of Gastroenterology.

We would like to emphasize the clinical relevance of this topic regarding its, until recently, unrecognized features and share our small case-series experience (Table 1).

Curiously, in both cases symptoms developed long (fourteen and ten months, respectively) after starting therapy. This has rarely been addressed and may difficult the diagnosis.

The primary care physicians were informed and advised to switch class of medication in these cases. There were no recurrences of symptoms during follow-up.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical features of two cases of sprue-like enteropathy associated with olmesartan. F, Female; hypoK, hipokalemia; hypoAlb, hypoalbuminemia; hypoMg, hypomagnesemia.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Age</td>
</tr>
<tr>
<td>---------</td>
<td>-----</td>
</tr>
<tr>
<td>F</td>
<td>72</td>
</tr>
<tr>
<td>F</td>
<td>52</td>
</tr>
</tbody>
</table>

DOIs of original articles:
http://dx.doi.org/10.1016/j.jpge.2015.10.007,
http://dx.doi.org/10.1016/j.jpge.2015.12.003,
http://dx.doi.org/10.1016/j.jpge.2015.09.005

http://dx.doi.org/10.1016/j.jpge.2016.06.004

2341-4545 © 2016 Sociedade Portuguesa de Gastroenterologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
References


Luis Carvalho Lourenço*, Joana Carvalho e Branco, Liliana Santos, Alexandra Martins, Jorge Reis

Gastroenterology Department, Hospital Prof. Doutor Fernando Fonseca, Amadora, Portugal

* Corresponding author.
E-mail address: luisclourenco@gmail.com (L.C. Lourenço).